Rheumatology
in Perspective

By Olga Goodman, MD
A RheumaView publication

ES

Materiales para pacientes

EnglishРусскийEspañolPolski

Su recorrido
PacienteCuidador o familiarLector interesadoProfesional de la salud
Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication

Children & teens

Children Are Not Small Adults

Why rheumatic disease that starts in childhood is treated early and decisively — and what we weigh differently when the patient is still growing

Open to everyone

An adult’s joint is a finished building. It can be damaged, and we work hard to prevent that. A child’s joint is a construction site. The bones are still lengthening, the growth plates are still laying down new material, and the whole structure is being built while the family lives in it, goes to school in it and plays soccer in it.

Now imagine that a saboteur joined the crew on day one. Nobody says, “Let’s see how the building looks in six months.” You want the saboteur sent home, soon, and by a plan that doesn’t set the site on fire. That is the short version of why childhood-onset rheumatic disease is approached with even more urgency than the adult form, and why “aggressive” for a child never means “reckless.”

A girl in a hard hat stands beside a model house under construction, with scaffolding and a toy crane; a schoolbag and soccer ball are nearby.
Still under construction. Worth protecting from the start.

The clock runs longer

An adult diagnosed at 55 has decades to protect. A child diagnosed at eight has the rest of a very long life. Every year of uncontrolled inflammation in childhood is a year of damage that arrives early and has to be carried for a very long time.

Here is what that can look like. In a 30-year follow-up of 176 children first seen in the early 1980s, 59% were in remission off medication at the end, which is encouraging. But 34% still had active disease. Those children were treated with a small fraction of the options we have today. That is exactly the point: we now have the tools, and the goal is to use them in time. (source)

Three things a growing child has to protect

Growth. Inflammation itself can interfere with growth, and so can long or high-dose steroid courses. Inflammation in one knee can make that leg grow differently from the other. Arthritis in the jaw joint can change how the face develops. Hips do not forgive delay. Growing bones are also still building their strength, and both chronic inflammation and steroids can thin them. (source) You can read more in Joints, Entheses, and Growing Bones and When the Hip or Back Is Involved.

This is why US guidelines strongly recommend against long courses of oral steroids. A short course can serve as a bridge while the real medicine gets going, and joint injections can help in the meantime. But steroids are not the plan. They are the scaffolding.

Eyes. In some forms of childhood arthritis, especially in young children who test positive for ANA, the eye can become inflamed (uveitis) without redness, pain or a single complaint. Damage can build before anyone notices, including the child. That is why eye exams on a schedule are part of treatment, even when the joints look quiet: for at least five years after diagnosis, every three months for the highest-risk children, and every three months for a year after immune-suppressing medicine is stopped. (source)

In the spondyloarthritis types, the eye more often announces itself: red, painful, sensitive to light. That is a same-day call, not a “let’s see tomorrow.” See Eyes, Skin, and Bowel Symptoms and When Not to Wait.

A life in progress. A child’s full-time job is being a child: school, friends, sports, sleep, the first sleepover. Pain and fatigue take a bigger share of a smaller life. Control of the disease is not only about X-rays. It is about whether your daughter can hold a pencil at the end of the day. More in School, Friends, Sleep, and Mood.

What “aggressive” means for a child

The same three things as in adults, with one child-specific rule on top:

  1. Early. Treatment starts when the diagnosis is established. It does not wait for damage to appear on a scan.
  2. With a target. The goal is inactive disease, agreed in advance, not “somewhat better.”
  3. With checkpoints. There is a review date, often within about three months of starting or changing a medicine. If the target is not in sight, the plan changes. It does not drift.
  4. Escalate fast, use steroids briefly. If a medicine is not enough, we do not stay on it out of politeness. We step up, and we keep steroids short.

The medicine also fits the disease and the joints at risk. For sacroiliitis, guidelines recommend starting with an NSAID and adding a TNF inhibitor if that is not enough, and they advise against methotrexate alone. For enthesitis, a TNF inhibitor is preferred over methotrexate. Details are in What Treatment Is Trying to Achieve, NSAIDs, Injections, and Conventional DMARDs and Biologic and Targeted Treatments. (guidelines)

What the evidence does and does not say. In the TREAT trial of 85 children with new polyarticular JIA, 40% of those given early combination treatment reached inactive disease at six months, versus 23% on methotrexate alone. That result did not quite reach statistical significance for the study’s main question. In ACUTE-JIA, a smaller trial of 60 children, inactive disease was reached by 68% on a TNF inhibitor plus methotrexate versus 20% on methotrexate alone, though that outcome was analyzed after the fact. The researchers’ own conclusion: early intensive treatment gives better outcomes, but giving every child a biologic from day one is not currently justified. The sensible course is to move quickly for the children at highest risk. (source) So the evidence supports the direction, not a single recipe. The guidelines themselves note that the evidence is generally limited, which is why decisions are made one child at a time.

What we weigh before choosing a medicine

  • Size and growth. Doses are calculated for the child and recalculated as they grow. Height and growth are tracked as part of every treatment plan.
  • Infections and vaccines. Before some medicines, we check past infections, vaccinations and tuberculosis exposure. Non-live vaccines are generally given during treatment, and live vaccines need a specific decision. Details are in Infections, Vaccines, and Treatment Safety.
  • The eyes. A schedule is set before the first dose, not after the first problem.
  • Less data than in adults. Some medicines have been studied less in children, and we say so openly, including when something is used off-label.
  • Injections and daily routine. A medicine that cannot fit into your family’s mornings is a medicine that won’t get taken. Many children handle injections better than their parents do.
  • The teenager in the room. Private time with the doctor, honest talk about alcohol, vaping and sexual health, and pregnancy planning when methotrexate is involved. See Growing Up With Treatment.
  • The child’s own voice. We explain things to the child, not over the child’s head.
A girl points to a planner while a woman doctor and the girl's father listen attentively at the same table.
The plan should fit the child—and include the child.

“But isn’t that a lot of medicine for a child?”

It is a fair worry, and you should ask it out loud. Here is one honest data point. In a large German registry, serious adverse events were somewhat more frequent with etanercept or adalimumab than with methotrexate alone (about 4.5 to 4.7 versus 2.6 per 100 patient-years), while malignancy was not significantly more frequent. Long follow-up in children is still being collected, which is one reason monitoring is part of the plan. (source)

The other half of the ledger is what uncontrolled disease does to joints, growth and eyes. That comparison is the subject of Afraid of the medication. What about the disease? And if you dream of a medicine that works on day one, has no side effects and needs no blood tests, we wrote an essay about it. Spoiler: it hasn’t been invented.

“She’ll grow out of it”

Some children do reach remission, including remission off medication. But nobody can tell on day one which child that will be, and “growing out of it” can quietly turn into growing up with damage. Children do outgrow shoes every six months. They do not outgrow joint damage.

A girl wearing new sneakers holds up a tiny outgrown shoe; two smaller pairs sit beside her, with height marks on the wall.
A bigger shoe size is not a treatment plan.

When a child is in remission, stopping medicine should be a planned decision, not a quiet fade. Flares can follow, and eye checks continue after stopping. See Remission, Flares, and the Future. And if your child is on a waiting list for pediatric rheumatology, that delay is not your failure. Ask your pediatrician what can be done while you wait.

What you can do

  • Keep a short daily-life record: morning stiffness, limping, missed activities, sleep. It helps the team judge benefit, as explained in Is Treatment Working?
  • Use the Visit Planner to prepare for appointments.
  • Ask four questions: What is our target, and when do we check? What are we protecting (growth, eyes, hips)? What happens if we are not at target by that date? Who do we call the same day?
  • Put the eye exam schedule on the calendar next to the medicine schedule.
  • Look ahead to adulthood with the Transition Passport.

In short

  • A child’s joints are still under construction, so delay costs more.
  • Growth, eyes and a childhood are what we are protecting, along with the joints.
  • “Aggressive” means early, with a target, with checkpoints, and with steroids kept short. It does not mean “the strongest drug for everyone.”
  • The treatment is matched to the child, and the child is part of the conversation.

A child’s arthritis is not a smaller version of an adult’s. It is a different problem with a longer clock, and it deserves a faster answer.

Educational material, not a prescription. Do not start, stop or change treatment on the basis of this article alone. Discuss decisions with your child’s treating physician.

Sources

© 2026 Olga Goodman, MD · RheumaView

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: How treatment worksJuvenile spondyloarthritisPatient educationTreatmentTreatment decisions